E H A / Fellowships
Fellowships
The aim of the program is to promote European hematological research and in particular to support junior basic and clinical researchers in the development of their careers.
EHA FELLOWSHIP PROGRAM
One of EHA's goals is to promote the career development of junior scientists involved in basic, clinical and experimental research in hematology. EHA funds research fellowships, including the long-established José Carreras Foundation - EHA Young Investigator Fellowship, for researchers in the field of malignant and non-malignant hematology. Each grant is for a two-year period.
Awards will be made at the 14th Congress of EHA in Berlin next year and will be payable from January 2010.
EHA PARTNER FELLOWSHIP PROGRAM
Sharing knowledge and expertise and creating strong, dynamic networks for hematology is the EHA Mission. One of EHA's goals is to promote the career development of young scientists involved in basic, clinical and experimental research in hematology in new accession and EU candidate countries.
Therefore a Partner Fellowship Program has been developed. Read more »
EHA-ASH Research Exchange Award
The EHA-ASH Research Exchange Award was offered for the first time in 2006. This new award has been developed as a partnership between the European Hematology Association (EHA) and the American Society of Hematology (ASH) to provide hematologists in training or early in their careers the opportunity to conduct research in another country. Read more »
EHA-ASH Award winners 2009
Dr. Freda Passam, MD, PhD
Home institution: Medical School of Crete, Greece
Host institution: Research Center of Thrombosis and Hemostasis at the Beth Israel Deaconess Medical Center in Boston, United States
Title: "Role of the thiol isomerase ERp5 in thrombus formation"
Dr. Carmen Schweighofer, MD
Home institution: University of Cologne, Germany
Host Institute: The University of Texas M. D. Anderson Cancer Center, United States
Title: "Genomic aberrations predict outcome in patient with chronic lymphocytic leukemia (CLL) treated with frontline FCR chemoimmunotherapy"
Last updated on Friday 22 May 2009.
